Please try another search
For the three months ended 28 February 2022, Hyundai Pharmaceutical Co Ltd revenues increased 23% to W37.45B. Net income totaled W1.17B vs. loss of W963.4M. Revenues reflect Pharmaceutical segment increase of 16% to W31.2B, Food segment increase from W1.37B to W4.48B. Net Income reflects Pharmaceutical segment income totaling W2.15B vs. loss of W935.3M, Food segment income totaling W426.8M vs. loss of W116.8M.
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Total Revenue | 37451.09 | 33804.13 | 38277.54 | 37300.83 |
Gross Profit | 16302.79 | 13097.2 | 15725.65 | 15551.61 |
Operating Income | 2577.13 | -3217.27 | 2210.32 | 487.18 |
Net Income | 1174 | -2416.15 | -229.66 | 436.05 |
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Total Assets | 159976.32 | 163857.42 | 174601.13 | 174734.62 |
Total Liabilities | 73123.2 | 77257.09 | 85039.29 | 84026.11 |
Total Equity | 86853.12 | 86600.32 | 89561.85 | 90708.52 |
Period Ending: | Feb 28, 2022 | Nov 30, 2021 | Aug 31, 2021 | May 31, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -639.67 | 5132.21 | 1562.43 | 1696.2 |
Cash From Investing Activities | -1708.43 | -27.75 | -6007.86 | 3293.85 |
Cash From Financing Activities | 35.7 | 3251.28 | 13396.66 | 11130.45 |
Net Change in Cash | -2312.4 | 8355.74 | 8951.24 | 16120.5 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review